concizumab   Click here for help

GtoPdb Ligand ID: 11182

Synonyms: Anti-TFPI | mab2021 | NN7415
Compound class: Antibody
Comment: Concizumab is a clinical stage anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. It is a humanised IgG4 construct that was developed by Novo Nordisk as a novel therapeutic for genetic bleeding disorders [2]. Concizumab binds to the Kunitz-type protease inhibitor (KPI) 2 domain of TFPI and blocks its interaction with the active site of FXa [1]. TFPI is an endogenous anticoagulant protein whose pharmacological inhibition restores hemostasis [6].
Click here for help
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
9636 concizumab
Synonyms Click here for help
Anti-TFPI | mab2021 | NN7415
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 447
Other databases
GtoPdb PubChem SID 434122242
Search PubMed clinical trials concizumab
Search PubMed titles concizumab
Search PubMed titles/abstracts concizumab